DDR Defective Tumors Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global DDR Defective Tumors Market is segmented By Molecule Type (Biologics, Small Molecules) By Cancer Type (Ovarian, Prostate, Breast, Pancreatic, Others) By End User (Hospitals, Cancer Research Centers, Specialty Clinics) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Market Overview

The Global DDR Defective Tumors market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

DDR defect is an innate characteristic of tumor cells that participates not just in cancer initiation, but in cancer advancement and metastasis from considerable aspects. Advanced DDR gene alterations and genomic instability are hallmarks of metastatic growth. DDR (DNA damage response) deficiencies in cells drive tumor building by boosting DNA mutations, which even deliver cancer-specific susceptibilities that can be targeted by synthetic lethality-based therapies.

Market Scope

For more details on this report – Request for Sample

Market Dynamics: Drivers & Restraints

Increase in Clinical Research Advancements

It is expected that the global market growth will be boosted owing to the increase in clinical research advancements in DDR defective tumors during the forecast period. The success of PARP inhibitors like olaparib in treating cancers with DNA-repairing deficiency (e.g. BRCA1 or BRCA2 mutation) by utilizing synthetic lethality-based therapy has fueled the search for more targetable components in the DDR signaling pathway through synthetic lethality, including DNA-PK, ATR, ATM, CHK1, and WEE1. Numerous DDR kinase inhibitors have been discovered after years of effort, and some of them are undergoing clinical trials, showing promising results for cancer therapy. For instance, the ImmunoProst Trial, sponsored by Hospital Moinhos de Vento, is currently active and investigating Nivolumab in Prostate Cancer With DNA Repair Defects in Phase 2 clinical investigation.

Additionally, the rise in cancer cases and growing market developments are among other factors that are expected to contribute to the global market growth during the forecast period.

Stringent Regulatory Authorities

Nevertheless, stringent regulations for approval from regulatory authorities, high development costs and high treatment costs are in developing and underdeveloped countries are estimated to hamper the global market growth during the forecast period.

Segment Analysis

The global DDR defective tumors  market is segmented based on molecule type, cancer type, end user and region.

Biologics Molecule Type is Expected to Dominate Market

The biologics segment of the global market is estimated to dominate the global market during the forecast period due to the increasing number of clinical trials investigating biologics for DDR defect tumors. For instance, according to clinicaltrial.gov, M.D. Anderson Cancer Center is sponsoring a study recruiting patients with DNA damage response (DDR) deficient advanced solid tumors to determine the safety and tolerability of the combination of berzosertib (M6620) and avelumab, with an estimated completion date of 2024. Additionally, Asan Medical Center is sponsoring another study recruiting for a randomized open-labeled phase 2 study of maintenance Olaparib with or without Durvalumab for DDR gene mutated advanced biliary tract cancer following platinum-based chemotherapy, with an estimated completion date of 2024.

Geographical Analysis

North America is Expected to Dominate the Global Market

North America is estimated to dominate the global market during the forecast period owing to the increasing research advancements by key market players in the region. For instance, in June 2021, Pfizer Inc. dosed the first participant in TALAPRO-3, a multinational, randomized, double-blind, placebo-controlled Phase 3 clinical trial. 

The study is estimated to assess the effectiveness and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in males with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC). 

Moreover, in July 2023, KSQ Therapeutics, Inc., a US-based clinical-stage biotechnology corporation, entered a worldwide license and cooperation contract with Roche for the development and commercialization of KSQ-4279, a first-in-class, powerful, and selective small molecule inhibitor of USP1, a protein that controls DNA damage response (DDR) in a form distinctive from other techniques, including PARP inhibitors.

COVID-19 Impact Analysis

The impact of the COVID-19 pandemic on hematology and oncology clinical trials has been significant, with immediate and delayed consequences. To manage the influx of COVID-19 patients, many academic institutions and participating hospitals have had to reassign research staff and resources, leading to the suspension of routine clinical research activities. 

Furthermore, trials testing treatments for COVID-19 have been given priority over other trials. Travel restrictions have also resulted in the cancellation of research-related appointments, including site selection or qualification, source data verification, drug accountability, audit, and site staff training by CROs and sponsors. As a result, there has been a sharp decline in recruitment for ongoing trials, and the launch of new hematology and oncology studies might be delayed during the peak of the pandemic.

Key Developments

• In January 2023 Aprea Therapeutics, Inc., a biopharmaceutical corporation concentrated on designing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, dosed the first patient in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s principal ATR inhibitor for the therapy of cancers with DDR mutations. 
• In July 2021, Artios Pharma Limited (Artios), a top DNA Damage Response (DDR) corporation using a wide DDR-based platform and small molecule drug discovery abilities to design a mixed pipeline of development nominees for the therapy of cancer, secured a US$153 million (£110 million) Series C financing to fund further development of its promising clinical-stage pipeline.

Competitive Landscape

The major global players in the market include Artios Pharma Limited, AstraZeneca, Aprea Therapeutics, Inc., KSQ Therapeutics, Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Daiichi Sankyo Company Limited., Chordia Therapeutics Inc. and Repare Therapeutics.

Why Purchase the Report?

• To visualize the global DDR defective tumors market segmentation based on molecule type, cancer type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of DDR defective tumors market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global DDR defective tumors market report would provide approximately 61 tables, 58 figures and 184 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies